SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the third quarter of 2014 are expected to be approximately $15 million and that non-GAAP earnings per diluted share are expected to be between $0.33 and $0.37. This compares with prior guidance issued on August 4, 2014 for total revenues to be between $13 million and $14 million and for non-GAAP earnings per diluted share to be between $0.26 and $0.29.
Ligand also expects total revenues for the fourth quarter to be between $22.5 million and $24.5 million. Ligand’s guidance for the 2014 full year remains unchanged, with total revenues expected to be between $64 million and $66 million and non-GAAP earnings per diluted share expected to be between $1.50 and $1.55. The non-GAAP earnings per diluted share guidance for the 2014 third quarter and full year does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock-based compensation expense and debt discount and issuance cost amortization.
Help employers find you! Check out all the jobs and post your resume.
Ligand also expects total revenues for the fourth quarter to be between $22.5 million and $24.5 million. Ligand’s guidance for the 2014 full year remains unchanged, with total revenues expected to be between $64 million and $66 million and non-GAAP earnings per diluted share expected to be between $1.50 and $1.55. The non-GAAP earnings per diluted share guidance for the 2014 third quarter and full year does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock-based compensation expense and debt discount and issuance cost amortization.
Help employers find you! Check out all the jobs and post your resume.
